NCT02718716 - Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions

Thrombocytopenia

Interventions

DRUG

UCB7665

"* Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"

Trial Locations (29)

Unknown

Tp0001 1101, Adelaide

Tp0001 1302, Pleven

Tp0001 1301, Sofia

Tp0001 203, Olomouc

Tp0001 201, Prague

Tp0001 1201, Tbilisi

Tp0001 401, Berlin

Tp0001 403, Düsseldorf

Tp0001 404, München

Tp0001 502, Florence

Tp0001 506, Torino

Tp0001 503, Udine

Tp0001 505, Vicenza

Tp0001 601, Chisinau

Tp0001 702, Bialystok

Tp0001 703, Gdansk

Tp0001 701, Lodz

Tp0001 704, Poznan

Tp0001 705, Warsaw

Tp0001 802, Brasov

Tp0001 801, Bucharest

Tp0001 803, Craiova

Tp0001 902, Madrid

Tp0001 903, Madrid

Tp0001 901, Valencia

Tp0001 1001, London

Tp0001 1002, London

Tp0001 1003, London

Tp0001 1004, Truro